Preparing your space
Preparing your space
Conditions & Recovery · Oncology Brothers · May 20, 2026
In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafe
Originally published by Oncology Brothers. We curate and add context; they did the reporting.
Read the full story at Oncology Brothers ↗